Mineralys Therapeutics, Inc. (MLYS) Dividend History

Company News

• Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

  Mineralys Therapeutics announced positive results from the Phase 3 Launch-HTN trial of its drug lorundrostat for the treatment of uncontrolled or resistant hypertension. The trial demonstrated clinically meaningful and sustained reductions in systolic blood pressure with a favorable safety profile.

  GlobeNewswire Inc.
• Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

  Mineralys Therapeutics announced positive results from the Advance-HTN trial, which evaluated the efficacy and safety of their drug lorundrostat in patients with uncontrolled or resistant hypertension. The 50 mg dose of lorundrostat demonstrated a significant reduction in 24-hour ambulatory blood pressure, with a favorable safety profile.

  GlobeNewswire Inc.
• Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

  Mineralys Therapeutics has completed enrollment for its pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company expects to announce topline data in Q1 2025.

  GlobeNewswire Inc.
• MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!

  Mineralys Therapeutics, Inc. (MLYS) released its Q2 2024 financial results, which missed analyst consensus estimates, causing a sharp drop in the company's stock price. Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mineralys investors.

  GlobeNewswire Inc.
• Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

  Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024

  GlobeNewswire Inc.